Navigation Links
Medivation Announces First U.S. Presentation of Data From Dimebon,Phase 2 Alzheimer's Disease Trial at American Academy of Neurology,Annual Meeting

-- New Subset Analyses To Be Presented --

SAN FRANCISCO, April 24, 2007 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that data from the Company's Phase 2 efficacy study of Dimebon(TM) in Alzheimer's disease will be presented for the first time in the United States at the American Academy of Neurology's 59th Annual Meeting in Boston on Thursday, May 3, at 4:15 p.m. Eastern time. The presentation will include new data from both the mild and moderate subgroups of patients with Alzheimer's disease. Medivation will hold a teleconference on Friday, May 4, at 9:00 a.m. Eastern time with David Hung, M.D., president and chief executive officer of Medivation, Lynn Seely, M.D., chief medical officer, and Rachelle S. Doody, M.D., Ph.D., lead investigator, to discuss the data.

Dr. Doody will present the data (abstract #S51.003), Dimebon Improves Cognition, Function and Behavior in Patients with Mild-Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Study, during the "Aging and Dementia" session of the conference. Dr. Doody holds the Effie Marie Cain Chair in Alzheimer's Disease Research at the Alzheimer's Disease and Memory Disorders Center, in Houston.

In addition, these data have been selected by the American Academy of Neurology for inclusion in the Scientific Topic Highlights session on Thursday, May 3, at 6:00 p.m. Eastern time. During this session, expert moderators will summarize the most interesting and relevant research at the meeting in a particular topic.

Teleconference/Webcast Details

To participate in the live call by telephone, please dial 800-289-0485 from the U.S. or 913-981-5518 internationally. Individuals interested in listening to the live call via webcast may do so by visiting www.medivation.com. A replay of the webcast will be available on the Company's website for 3 0 days.

About Dimebon

Dimebon, the Company's lead product candidate, is an orally-available small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer's disease and Huntington's disease, making it a potential treatment for these and other neurodegenerative diseases. Based on the clinical and preclinical data generated to date, Medivation believes that Dimebon operates by a novel mechanism of action and may exert a neuroprotective effect in multiple areas of the central nervous system. Dimebon appears to block a new target that involves mitochondrial pores, which are believed to play a role in the cell death that is associated with neurodegenerative diseases and the aging process. Medivation is currently evaluating Dimebon in clinical trials in both Alzheimer's and Huntington's diseases.

Six-month results from the Phase 2 efficacy study demonstrated that patients treated with Dimebon were significantly improved compared to patients taking placebo on all five efficacy endpoints studied, which assessed cognitive function, memory, ability to perform tasks of daily living, global function and behavior. Dimebon was well tolerated in the study.

About Medivation

Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to www.medivation.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Liti gation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. You are also cautioned that none of the Company's product candidates has been approved for sale, that significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and that Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Medivation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2006, include more information about factors that could affect the Company's financial and operating results.

CONTACT: Patrick Machado, Chief Financial Officer of Medivation, Inc.,+1-415-543-3470, ext. 201; or Jani Bergan of WeissComm Partners,+1-415-946-1064, for Medivation, Inc.

Web site: http://www.medivation.com//

Ticker Symbol: (NASDAQ-NMS:MDVN)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Medivation Announces Presentation of Full Top-Line Data From Dimebon Six-Month Trial at Major International Alzheimers Disease Conference
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Eyevensys, a private biotechnology company developing its ... that enables the safe, local, sustained production of therapeutic ... of ophthalmic diseases, announces it has received approval from ... to advance its technology into clinical development. ... The EyeCET platform uses ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
Breaking Medicine Technology:
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Providing for ... understand the estate planning process, or where to even begin. “Now more than ever ... you are to properly protect yourself and your family,” said attorney Lisa Edgar Dickman, ...
(Date:4/21/2017)... ... April 21, 2017 , ... Westside Dental Associates ... dental care since 1985. After thirty-two years, Dr. Latner has become one of the ... my numerous clients over the years with all their dental needs,” said Dr. Latner, ...
(Date:4/21/2017)... ... ... Each year, everyone is urged to give back to the earth on April ... a better future. However, supporting the environment should be an everyday practice. , ... to five times more polluted than outdoor air, reports the Environmental Protection Agency -- ...
(Date:4/21/2017)... Houston, Texas (PRWEB) , ... April 21, 2017 ... ... repeal…. sound familiar? These are five common elements between the Obamacare program ... feral hog control program which uses Warfarin poison to kill hogs. , ...
(Date:4/21/2017)... ... April 21, 2017 , ... Indiana ... significant bandwidth upgrade infrastructure service to Tele-Media Solutions. IFN is delivering Multi-Gigabit ... IFN’s consortium member-owners, Tele-Media Solution’s protect transport with 3GB Dual Access Internet access ...
Breaking Medicine News(10 mins):